Douglas West, MD
Urology · Jefferson City, MONPI 1255352043
Payments from drug & device makers
Across 57 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$406
- Boston Scientific$183
- Myriad Genetic Laboratories, Inc.$104
- Coloplast$56
- Convatec Inc.$40
- Merck$39
- plus $197 from 8 others
What the payments were for
- Food & beverage$1,023100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 22 | $406 |
| Boston Scientific | 10 | $183 |
| Myriad Genetic Laboratories, Inc. | 5 | $104 |
| Coloplast | 3 | $56 |
| Convatec Inc. | 3 | $40 |
| Merck | 2 | $39 |
| Travere Therapeutics, Inc. | 2 | $37 |
| AbbVie | 2 | $33 |
| Teleflex LLC | 2 | $32 |
| Bayer | 2 | $31 |
| Neotract Inc. | 1 | $24 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $17 |
| Amgen | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
How this compares
$1,023 in reported general payments places this provider in the 20th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 57 | $38,416 |
| GemtesaVibegron | 36 | $28,115 |
| Tamsulosin Hcl | 854 | $12,629 |
| Mirabegron ErMirabegron | 14 | $9,689 |
| Finasteride | 428 | $6,446 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 62 | $2,544 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $2,437 |
| Methenamine Hippurate | 14 | $1,954 |
| Silodosin | 14 | $1,593 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 65 | $1,373 |
| Dutasteride | 36 | $957 |
| Oxybutynin Chloride ErOxybutynin Chloride | 53 | $888 |
| Doxycycline Hyclate | 23 | $650 |
| Cefdinir | 46 | $526 |
| Allopurinol | 20 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $406 | $38,41657 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 250 urology providers in Missouri.
Other urology in Jefferson City
- Travis BullockSaint Louis$751K
- Michael JohnsonSaint Louis$471K
- Gregory AuffenbergSaint Louis$468K
- Gerald AndrioleSaint Louis$308K
- Hing LaiSaint Louis$173K
- Samuel KuykendallKansas City$141K
- Donald NeffKansas City$141K
- Gerald ParkNorth Kansas City$136K
- Mark WakefieldColumbia$122K
- Gautum AgarwalSaint Louis$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.